KRTL Biotech Highlights Ophthalmic Pharmaceutical Capabilities to Address Vision Care Needs in Emerging and Global Markets

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company") today announced a new category spotlight on ophthalmology, emphasizing its plans to support access to essential eye care treatments through its subsidiary, KRTL Biotech Inc., and Bolivian manufacturing partner, Industria Químico-Farmacéutica SIGMA Corp. S.R.L. ("SIGMA").

The ophthalmic pharmaceutical market continues to expand globally, with increasing demand for solutions to treat infections, allergies, inflammation, and chronic conditions such as dry eye and glaucoma. Access to affordable and reliable ophthalmic products is particularly important in underserved health systems and rural populations where vision care options are limited.

KRTL Biotech, through its strategic partnership with SIGMA, is actively evaluating and preparing formulations aligned with these needs, including antibiotic eye drops, antihistamines, and preservative-free ocular solutions. SIGMA’s GMP-compliant manufacturing facility supports aseptic production processes and sterile packaging suitable for ophthalmic dosage forms. Products currently sold in Bolivia include Gentamicol, a broad-spectrum antibiotic eye drop; Lubricol, an ocular lubricant; and Glaucol-T, formulated to help manage intraocular pressure.

"Vision health is often overlooked, but it is a fundamental part of public health," said Patricia Wilstermann, CEO of SIGMA Corp. "We are proud that our platform has the capacity and quality systems to support the development and export of safe, effective ophthalmic medicines to meet growing regional and international demand."

Ophthalmic products will form part of KRTL Biotech’s broader portfolio strategy to deliver high-need, high-compliance treatments into the U.S. and LATAM markets. The Company is currently researching regulatory pathways for select formulations under the U.S. FDA's Over-the-Counter (OTC) monograph system and Abbreviated New Drug Application (ANDA) processes, as well as exploring opportunities in institutional procurement channels.

"Our pharmaceutical expansion is guided by medical relevance and regulatory scalability," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Ophthalmology represents a strong growth area, and with SIGMA’s validated production environment, we are well-positioned to deliver products that align with both clinical value and access objectives."

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.

About Industria Químico Farmacéutica SIGMA Corp SRL

SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains statements and information that, to the extent that they are not historical fact, may constitute  “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.